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Background.T - S P O T . TB is an interferon gamma release assay for detecting Mycobacterium tuberculosis infection. The requirement
to process within 8 hours is constraining, deters use, and leads to invalid results. Addition of T Cell Xtend reagent may allow
delayed processing, but has not been extensively ﬁeld tested. Design. Consecutive AFB smear positive adult tuberculosis patients
were prospectively recruited in Dar es Salaam, Tanzania. Patients provided a medical history, 1–3 sputum samples for culture
and 1 blood sample which was transported to the laboratory under temperature-controlled conditions. After overnight storage,
25μLo fTC e l lXtend reagent was added per mL of blood, and the sample was tested using T-SPOT.TB. Results. 143 patients
were enrolled: 57 patients were excluded because temperature control was not maintained, 19 patients were excluded due to red
blood cell contamination, and one did not provide a sputum sample for culture. Among 66 evaluable patients, overall agreement
between T-SPOT.TB and culture was 95.4% (95%CI; 87.1–99.0%) with Kappa value 0.548. Sensitivity of T-SPOT.TB when using T
Cell Xtend reagent was 96.8% (95%CI; 88.8–99.6%). Conclusions.W h e nTC e llXtend reagent is added to specimens held overnight
at recommended temperatures, T-SPOT.TB is as sensitive as the standard assay in patients with tuberculosis.
1.Introduction
The T-SPOT.TB (Oxford Immunotec Ltd, Abingdon, UK)
is an interferon gamma release assay (IGRA) for detection
of latent Mycobacterium tuberculosis infection (LTBI). This
assay detects T-lymphocytes speciﬁc for M. tuberculosis
antigens that are absent from M. bovis BCG and most envi-
ronmental mycobacteria [1]. Currently, T-SPOT.TB must be
performed within 8 hours of sample collection. Logistically,
this requires that patients have blood drawn early enough
to transport the sample to the laboratory, which must assay
samples on the day of receipt. This precludes batching
samples, which would save resources and testing supplies.
Moreover, in many countries, laboratories are centralized
and are not in close proximity to where the blood sample
is drawn. Therefore, it is not possible to transport samples to
arrive at the receiving laboratory for processing on the same
day.
To allow greater test processing ﬂexibility, the manufac-
turer of T-SPOT.TB developed a proprietary reagent called T
Cell Xtend, which they report can be added to whole blood
samples stored at 10–25◦C to increase this timeframe up to
32 hours [2].
2.MaterialsandMethods
The ethical review boards of Dartmouth Medical School
(Hanover NH), the National Institute for Medical Research2 Tuberculosis Research and Treatment
(Dar es Salaam, Tanzania) and Muhimbili University of
Health and Allied Sciences (MUHAS, Dar es Salaam, Tanza-
nia) approved the study. The study was conducted according
to the principles of good clinical practice and under the
International Conference on Harmonization guidelines.
2.1. Participant Enrolment. All AFB smear positive indi-
viduals referred for initiation of TB treatment to one of
two National Tuberculosis and Leprosy Programme (NTLP)
TB treatment clinics in Dar es Salaam, Tanzania, were
approached by a trained study nurse to determine their
interest in being included in the study. The study nurse
explained the study and answered any questions in the
patient’s native language. The participants then signed the
approved informed consent or, in the presence of a witness,
indicated their signature with a ﬁngerprint. All participants
provided a medical history, up to three sputum samples and
a blood sample for testing by IGRA and were oﬀered HIV
testing according to the NTLP guidelines.
2.2. IGRA Testing. A single tube of blood was drawn from
each participant. During the initial enrolment period, blood
samples were transported to the laboratory under ambient
temperature conditions (maximum average temperatures
during the enrolment months were 28◦Cf o rS e p t e m b e ra n d
29◦C for October) and, in the latter enrolment period, under
temperatures ensured as <25◦Cb yu s eo fat e m p e r a t u r e
control shipping box (GreenBox Thermal Management
System (Thermosafe Brands, Arlington Heights, IL, USA)).
The blood samples were then stored overnight in an air
conditionedlaboratory(<25◦C)andtestedusingT-SPOT.TB
according to the manufacturer’s instructions for use [3].
TC e l lXtend reagent was added to each blood sample
at 25μL/mL blood, mixed and incubated for 20 minutes
a tr o o mt e m p e r a t u r eb e f o r ep r o c e s s i n g .P e r i p h e r a lb l o o d
mononuclear cells (PBMC) were harvested by Ficoll den-
sity gradient centrifugation using Leucosep tubes (Oxford
Immunotec, Abingdon, UK). The PBMCs were washed,
counted using a hemocytometer, and plated at 2.5 × 105
cells per well into a membrane-bottomed plate, coated with
anti-interferon gamma antibody. PBMCs were incubated
overnight in the presence of the provided TB antigens
(ESAT-6 and CFP10) along with controls (positive mitogen
control and a nil control). The PBMCs producing interferon
gamma were revealed as spots by incubation with an enzyme
conjugated secondary antibody for interferon gamma and
a colour producing enzyme substrate. Spots were counted,
and clinical result was recorded according to the approved
algorithm where, compared to the nil control, 6 spots and
above are positive and 5 spots and below are negative.
Results with a low-mitogen response (<20 spots) or a high-
nil control response (>10 spots) were recorded as invalid.
2.3. Mycobacterial Studies. AFB smears were done according
to the Ziehl-Neelsen method by trained research personnel.
SputumwasculturedformycobacteriaonLowensteinJensen
slants.
2.4. Statistical Analyses. Sensitivity was calculated as the
number of T-SPOT.TB positive samples divided by the
number of culture positive samples multiplied by 100. 95%
conﬁdence limits were calculated. The Kappa statistic was
used to measure overall agreement between culture and T-
SPOT.TB results. Analyses were conducted using Excel.
3. Results
A total of 143 participants were enrolled into the study
(Figure 1). The initial 57 blood samples drawn at one clinic
were transported and stored at ambient temperatures prior
to processing. After processing, it was recognized that these
specimens were not reliably kept at temperatures below
25◦C (the required temperature per protocol), and therefore
these 57 samples were excluded from the ﬁnal sensitivity
analysis. Temperature control measures were instituted for
the subsequent collection of samples from an additional 86
participants. Nineteen of these 86 (22.1%) participants were
excluded because the laboratorian observed red blood cell
contamination in the PBMC layer so the PBMCs could not
be accurately counted. One of 86 (1.2%) participants failed
to provide a sputum sample for culture and was excluded.
Therefore, 66 results were available for analysis. The
participants were all black African and ranged in age from
18–60 years. The majority were male and BCG vaccinated
(71%and77%,resp.);17(26%)wereHIV-positive,24(36%)
were HIV-negative, and 25 (38%) declined testing.
Of the 66 T-SPOT.TB results, 61 (92.4%) were positive,
4 (6.1%) were negative, and 1 (1.5%) was invalid. The
overall agreement between the 65 valid T-SPOT.TB and
cultureresultswas95.4%(62/65:95%CI;87.1–99.0%)witha
Kappa value of 0.548. The sensitivity of the T-SPOT.TB assay
when run after delayed processing using the T Cell Xtend
reagent was 96.8% (60/62: 95%CI; 88.8–99.6%). Among 41
T-SPOT.TBresultsfromparticipantswithknownHIVstatus,
T-SPOT.TB results were positive in 14 (82.4%) of those who
were HIV-positive and 23 (95.8%) of those who were HIV-
negative (P>0.05). However, limiting to valid results from
culture positive patients, the sensitivity of the assay among
samples from HIV-positive participants was 92.9% (13/14).
In spite of exclusion because of protocol noncompliance,
results from the 57 samples transported at ambient tempera-
ture were also analyzed. Of the 57, 40 (70.2%) were positive,
11 (19.3%) were negative, and 6 (10.5%) was invalid. Com-
pared with the results from the 66 samples with temperature
control, false negative results among these 57 samples were
more common (P = 0.05). Results from 19 samples were
excluded because of red blood cell contamination showed
14 (73.7%) positive and 5 (26.3%) negative. Compared with
the results from 66 samples with temperature control, false
negativeresultsamongthese19werestatisticallysigniﬁcantly
more common (P = 0.04).
4. Discussion
T-SPOT.TB with delayed processing using T Cell Xtend
among patients with culture-conﬁrmed tuberculosis showed
high sensitivity, comparable to that reported for immediateTuberculosis Research and Treatment 3
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Figure 1: Patient ﬂow and testing results using T-SPOT.TB and T Cell Xtend, Dar es Salaam, Tanzania.
processing. In a recent meta-analysis of 14 studies of T-
SPOT.TB, (without Xtend) in low- and middle-income
countries, Metcalfe et al. reported sensitivity of 83% (95%
CI, 63–94%) among HIV-positive and -negative tuberculosis
patients [4].
This high sensitivity we observed is also consistent with
pilotstudieswiththeTCellXtend reagentcompletedatthree
clinical sites including the UK and South Africa [5]. Lenders
et al. studied the utility of T Cell Xtend, conducting T-
SPOT.TBassaysthesamedayascollectionandapproximately
one and two days after collection [6]. Spot counts from
66 specimens T-SPOT.TB assayed without the T Cell Xtend
reagent one day after collection were higher than those
processed on the day of collection. In contrast, spot counts
from 215 specimens assayed two days after collection with
the T Cell Xtend reagent were similar to those processed on
the day of collection. The T Cell Xtend reagent reduced the
proportionofsamplesthatchangedfrompositivetonegative
and vice versa (4.54% to 2.83%), but this was not statistically
signiﬁcant [6]. Wang et al. had similar high agreement
(98.2%) among 108 specimens of results of immediate T-
SPOT.TB and T-SPOT.TB with the T Cell Xtend reagent
processed 23–32 hours after collection [7].
In one of our patients, T-SPOT.TB was positive and
culture was negative (Table 1). This patient was an HIV-
infectedmale,whosubmittedthreesputumspecimenswhich
were 3+, 4+ and 1+ AFB smear positive, but all cultures were
negative. The T-SPOT.TB result was interpreted as positive,
given that the Nil control well showed 6 spots, Panel A 6, and
Panel B 15. Per the package insert, the test result is positive if
Panel A minus Nil control and/or Panel B minus Nil control
is 6 spots [3]. It may be that the T-SPOT.TB result was falsely
positive, or that the culture was falsely negative, perhaps
becausethepatienthadreceivedantituberculosistherapy.We
do not have follow-up data on the patient to know if they
Table 1: Overall agreement between TB culture and T-SPOT.TB.
T-SPOT.TB
Positive Negative Invalid
Culture Positive 60 2 1∗
N e g a t i v e 120
∗1/66 (1.5%) of T-SPOT.TB results was invalid due to a high nil control
result.
demonstrated a typical response to antituberculosis therapy,
or there was an alternative diagnosis made.
Our samples transported using a validated system for
temperature control at or below 25◦C showed sensitivity that
is equivalent to that reported for the same day T-SPOT.TB
assay [1, 3]. However, our study clearly illustrates the need to
controltemperature.Insub-SaharaAfricansettings,asimple
solution for shipment over long distances would be required,
such as the use of an insulated package system.
Red blood cell contamination also interferes with assay
reliability because the presence of large numbers of red
blood cells makes accurate counting of the PBMC fraction
diﬃcult, and therefore the required number of PBMCs
cannot be reliably determined. Red blood cell contamination
is more common when a hemocytometer is used (as in this
study), and the use of automated instruments that provide
ad i ﬀerential count of white blood cells would eliminate this
problem.
5. Conclusions
T-SPOT.TB can be run on blood samples not contaminated
with red blood cells and maintained overnight by the use
of T Cell Xtend reagent without aﬀecting the sensitivity of
the assay. Storage and transport of samples at temperatures4 Tuberculosis Research and Treatment
<25◦C are critical to obtaining optimum sensitivity, and use
of an automated cell counting instrument may correct the
reduced sensitivity observed with red blood cell contamina-
tion.
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